Kidney Energy Use and Scarring in ANCA Vasculitis
Part of Heart & circulation, Hormones & metabolism, Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This study looks at how kidney cells use energy and how that leads to scarring in people with ANCA vasculitis. It compares findings with people who have other kidney diseases to better understand and possibly treat kidney damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 90 years old.
- You have French health insurance (like the state system).
- Your doctor recommends a first-time kidney biopsy to diagnose your condition.
- You either have ANCA vasculitis (a blood vessel inflammation) confirmed by biopsy, or you have one of several other kidney diseases (like certain types of glomerular disease or diabetic nephropathy).
- You are not on dialysis, do not have a kidney transplant, and are not pregnant or breastfeeding.
- You are not under legal guardianship and are not already in another interventional study (except for those about ANCA vasculitis or IgA nephropathy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects and stores health information and possibly samples from people diagnosed with ANCA-associated vasculitis to help researchers learn more about the disease. It may help future studies, but it is mainly focused on collection rather than testing a new treatment.
This trial looks at how bacteria in the gut (microbiome) and substances in the body (metabonomics) relate to IgA nephropathy, a kidney condition. The goal is to understand patterns that may help explain the disease and improve future care.
This study follows people with ANCA-associated vasculitis to better understand the treatment using AAV. Your participation would mainly involve agreeing to be in the study and meeting the study’s disease criteria.
This study looks at different types of blood vessel inflammation (vasculitis) to learn more about why they happen and how they progress. By joining, you may help doctors better understand these conditions and improve future treatments.
This study follows patients with ANCA-associated vasculitis (a rare autoimmune disease affecting blood vessels) who receive rituximab, a medication that depletes certain immune cells. Researchers want to understand how the immune system recovers over time and whether this helps predict disease flares or relapses.
This trial tests a new medicine called ALE.F02 for people newly diagnosed with a type of kidney inflammation called rapidly progressive glomerulonephritis (RPGN) caused by ANCA vasculitis. The goal is to see if it can help rescue kidney function.
Hear when a new ANCA Associated Vasculitis (AAV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.